公开(公告)号：US10800754B2

公开(公告)日：2020-10-13

申请号：US16332993

申请日：2017-09-14

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takaharu Hirayama ,  Yasuhiro Hirata ,  Yusuke Tominari ,  Naoki Iwamura ,  Yusuke Sasaki ,  Moriteru Asano ,  Terufumi Takagi ,  Masanori Okaniwa ,  Masato Yoshida ,  Shinichi Imamura

IPC: C07D401/04 ,  C07D401/14 ,  C07D407/14 ,  C07D409/14 ,  C07D417/14 ,  A61P35/00

Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US09745325B2

公开(公告)日：2017-08-29

申请号：US15304727

申请日：2015-04-16

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masanori Okaniwa ,  Hiroshi Banno ,  Takaharu Hirayama ,  Douglas Robert Cary ,  Koji Ono ,  Naoki Iwamura

IPC: C07D513/04 ,  A61K31/429 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/455 ,  A61K31/5377

CPC classification number: C07D513/04 ,  A61K31/429 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/455 ,  A61K31/5377

Abstract: The present invention provides a fused heterocyclic compound that has CDK 8 and/or CDK 19 inhibitory activity. The present invention provides a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof.